Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
about
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's diseaseGingko biloba extract EGb 761®: clinical data in dementia.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsAlzheimer's disease: the benefits of early treatment.Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's DiseaseTarget symptoms and outcome measures: cognition.The role of functional assessment as an outcome measure in antidementia treatment.Environmental and dietary risk factors in Alzheimer's disease.Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Management of behavioral problems in Alzheimer's disease.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysisRole of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.Mechanistic comparison of current pharmacological treatments and novel phytochemicals to target amyloid peptides in Alzheimer's and neurodegenerative diseases.Acetylcholinesterase inhibitors promote angiogenesis in chick chorioallantoic membrane and inhibit apoptosis of endothelial cells.Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.Effects of donepezil on cognitive performance after sleep deprivation.
P2860
Q33911859-8A93974C-283A-4E90-9A39-4B6F204090D0Q34333365-E74B4637-D9FC-4847-80CD-4933787C6A4EQ34965949-C2D78DA4-CCA3-4117-A2A8-45FE95A09F55Q36249975-14625723-AAA0-4AB2-9A32-314BD16B6B32Q36562125-FC14B698-D06A-4C97-9F93-B6058ECC24C7Q36806620-687E8D39-4672-417A-95DA-530904AFDB32Q36806624-2965225D-CA2F-4094-95F3-C596C414F9F9Q36870079-039750B9-120D-461A-AF38-1E251F5B622BQ37169607-E2BA4206-69C3-4A1B-8714-4CEB009B56B1Q37193026-C2FC15A3-B67D-4F89-9423-31D16E159B58Q37680018-56AE1434-AF31-4816-8525-A555F39D3EF2Q37834619-C96FFE20-53D5-4C1B-ABA7-5B522A2A1FA9Q37967728-768A5935-22F8-4726-9023-15C319AA3ED6Q38700484-C6FBBEE1-6446-4887-982C-0C046EBD3227Q39418685-15908515-FC36-45FB-9AF8-C19FC075C8E7Q41848725-F287FD69-5984-43B5-95DD-CBA5AF45F864Q45866665-B53AB6A5-6BAA-49A6-9DED-36B852F30449Q48270020-55365466-C6FC-48E5-AF62-DA167D541003
P2860
Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@en
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@nl
type
label
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@en
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@nl
prefLabel
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@en
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@nl
P2093
P1476
Functional, cognitive and beha ...... moderate Alzheimer's disease.
@en
P2093
Donepezil MSAD Study Investigators' Group
S Gauthier
P304
P356
10.1185/030079902125001029
P407
P577
2002-01-01T00:00:00Z